The US drug company Cambrex whose Ceo is Shlomo Yanay will be sold for $ 2.4 billion

The US drug company Cambrex, whose chairman is Shlomo Yanai, is been sold to the $ 2.4 billion private equity fund Permira. The share price in the deal is $ 60, a 47% premium to the price set yesterday at the New York Stock Exchange.
The approval of the transaction depends on compliance with the suspended conditions and approval of Cambrak's shareholders. The companies estimate the deal will close in the fourth quarter of 2019.
Yanai, the former CEO of Teva, has been chairman of the company since 2014 and previously served as a director, starting in 2012. In 2018, the cost of hiring as chairman of Cambrakas was $ 400,000, of which $ 275,000 was cash and the rest was equity compensation.
Camberx is engaged in the development of raw materials for generic and innovative drugs. The company has over 2,000 employees in its operators in Europe and North America. In a statement released by Cambraks, it noted that two acquisitions of pharmaceutical companies that it made in the past two years (Halo Pharma in 2018 and Avista Pharma Solutions in 2019) contributed to increasing its manufacturing capabilities and diversifying its portfolio.